Dna methylation based test for monitoring efficacy of treatment
AssigneeRush University Medical Center
InventorsVictor Levenson, Anatoliy Melnikov, Roumen Balabanov, Dusan Stefoski
Life of this patent
Estimating the term…
Abstract
A DNA methylation-based test for efficiency of treatments is based on a plurality of genes. The test is suitable for monitoring treatment of subjects with neurological diseases, e.g., multiple sclerosis (MS); with cancer, e.g., breast and ovarian cancer, and with other diseases for which methylation of biomarkers differs in the diseased compared to the non-diseased state.
Claims21
A method of monitoring or determining treatment efficacy for a neuroinflammatory demyelinating disease in a subject, the method comprising determining methylation status or profile of a plurality of nucleic acid molecules isolated from the plasma of the subject, wherein the individual is undergoing treatment for the disease.
A method of diagnosing multiple sclerosis (MS) in a subject, the method comprising determining methylation status of a plurality of nucleic acid molecules isolated from plasma of the subject and determining that the subject has MS if the methylation status or profile of the nucleic molecules of the subject is similar to the methylation status generated from MS samples.
A method of monitoring or determining treatment efficacy for cancer in a subject, the method comprising determining methylation status or profile of a plurality of nucleic acid molecules isolated from the plasma of the individual, wherein the individual is undergoing cancer therapy.
A diagnostic kit for multiple sclerosis (MS) comprising reagents to test for methylation status of a plurality of biomarkers, wherein the biomarkers comprise a plurality of nucleic acid sequences that are differentially methylated in an individual suffering from MS compared to a control individual.
Dependencies are inferred from the claim text.